Beta Amyloid Peptide: Research Paper : Integrating Biomarker Outcomes into Clinical Trials for Alzheimer's Disease in Down Syndrome

Integrating Biomarker Outcomes into Clinical Trials for Alzheimer's Disease in Down Syndrome

Abstract

The NIH-funded Alzheimer's Biomarker Consortium Down Syndrome (ABC-DS) and the European Horizon 21 Consortium are collecting critical new information on the natural history of Alzheimer's Disease (AD) biomarkers in adults with Down syndrome (DS), a population genetically predisposed to developing AD. These studies are also providing key insights into which biomarkers best represent clinically meaningful outcomes that are most feasible in clinical trials. This paper considers how these data can be integrated in clinical trials for individuals with DS. The Alzheimer's Clinical Trial Consortium - Down syndrome (ACTC-DS) is a platform that brings expert researchers from both networks together to conduct clinical trials for AD in DS across international sites while building on their expertise and experience.

Keywords: Alzheimer's disease; clinical trials; down syndrome.

Conflict of interest statement

MSR is a consultant to AC Immune

This article originally appeared in the "https://pubmed.ncbi.nlm.nih.gov/33336224/" and has their copyrights. We do not claim copyright on the content. This information is for research purposes only. This Blog is made available by publishers for educational purposes only as well as to give you general information and a general understanding , not to provide specific advice. By using this blog site you understand that there is no client relationship between you and the Blog publisher. The Blog should not be used as a substitute for competent research advice.